Stock data
Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. (PTGX) reported net income of -US$130.15M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$158.13M | -US$130.15M | — |
| 2024 | — | — | US$252.84M | US$275.19M | — |
| 2023 | — | — | -US$93.65M | -US$78.95M | — |
| 2022 | — | — | -US$131.37M | -US$127.39M | — |
| 2021 | — | — | -US$125.84M | -US$125.55M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$213.47M | US$162.85M | — |
| 2026-03-31 | — | US$3.78M | — |
| 2025-12-31 | — | -US$44.38M | — |
| 2025-09-30 | — | -US$39.34M | — |
| 2025-06-30 | US$5.55M | -US$34.77M | — |
| 2025-03-31 | — | -US$11.65M | — |
| 2024-12-31 | — | US$131.67M | — |
| 2024-09-30 | — | -US$33.21M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.